Form 8-K - Current report:
SEC Accession No. 0000875320-25-000213
Filing Date
2025-08-04
Accepted
2025-08-04 16:06:07
Documents
13
Period of Report
2025-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vrtx-20250804.htm   iXBRL 8-K 26066
2 EX-99.1 ex-991_q22025.htm EX-99.1 250926
  Complete submission text file 0000875320-25-000213.txt   422375

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vrtx-20250804.xsd EX-101.SCH 1870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vrtx-20250804_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vrtx-20250804_pre.xml EX-101.PRE 12595
16 EXTRACTED XBRL INSTANCE DOCUMENT vrtx-20250804_htm.xml XML 2720
Mailing Address 50 NORTHERN AVENUE BOSTON MA 02210
Business Address 50 NORTHERN AVENUE BOSTON MA 02210 6173416393
VERTEX PHARMACEUTICALS INC / MA (Filer) CIK: 0000875320 (see all company filings)

EIN.: 043039129 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19319 | Film No.: 251180250
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)